Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology
Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology
Cardiovascular disease is the leading cause of death worldwide. Dual antiplatelet therapy (DAPT), with aspirin plus a P2Y12 inhibitor, is currently recommended as a default for patients after acute coronary syndrome (ACS) and following percutaneous coronary intervention (PCI). However, controversies arise over the role of aspirin, the optimal duration of DAPT after drug-eluting stent (DES) implantation, the choice of P2Y12 inhibitor and the variability in individual responses to antiplatelet agents. Recent data indicate that monotherapy with a P2Y12 inhibitor may have adequate anti-ischemic effects with lower bleeding risk. Additionally, discrepancies in DAPT duration recommendations and the optimal P2Y12 inhibitor, provides more uncertainty. We ask the question “does one size really fits all?” or should a more personalized strategy should be implemented.
CYP2C19 LOF, TEG 6S, acute coronary syndrome, antiplatelets, genotype, ischemic heart disease, personalized antiplatelet therapy, phenotype, platelet function testing
499-515
Elserwey, Ahmed
860ab4e4-973f-4a5e-8de4-ce904d2ba65c
Jabbour, Richard J.
fc38a4f8-18fe-4dd5-987d-47dfee7e1929
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Elserwey, Ahmed
860ab4e4-973f-4a5e-8de4-ce904d2ba65c
Jabbour, Richard J.
fc38a4f8-18fe-4dd5-987d-47dfee7e1929
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Elserwey, Ahmed, Jabbour, Richard J. and Curzen, Nick
(2024)
Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology.
Future Cardiology, 20 (9), .
(doi:10.1080/14796678.2024.2384217).
Abstract
Cardiovascular disease is the leading cause of death worldwide. Dual antiplatelet therapy (DAPT), with aspirin plus a P2Y12 inhibitor, is currently recommended as a default for patients after acute coronary syndrome (ACS) and following percutaneous coronary intervention (PCI). However, controversies arise over the role of aspirin, the optimal duration of DAPT after drug-eluting stent (DES) implantation, the choice of P2Y12 inhibitor and the variability in individual responses to antiplatelet agents. Recent data indicate that monotherapy with a P2Y12 inhibitor may have adequate anti-ischemic effects with lower bleeding risk. Additionally, discrepancies in DAPT duration recommendations and the optimal P2Y12 inhibitor, provides more uncertainty. We ask the question “does one size really fits all?” or should a more personalized strategy should be implemented.
Text
Main manuscript clean 19 07
- Accepted Manuscript
Restricted to Repository staff only until 2 August 2025.
Request a copy
Text
Tables and figures 19 07
- Accepted Manuscript
Restricted to Repository staff only until 2 August 2025.
Request a copy
Text
Title page
- Accepted Manuscript
Restricted to Repository staff only until 2 August 2025.
Request a copy
More information
Accepted/In Press date: 22 July 2024
e-pub ahead of print date: 2 August 2024
Additional Information:
Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.
Keywords:
CYP2C19 LOF, TEG 6S, acute coronary syndrome, antiplatelets, genotype, ischemic heart disease, personalized antiplatelet therapy, phenotype, platelet function testing
Identifiers
Local EPrints ID: 492655
URI: http://eprints.soton.ac.uk/id/eprint/492655
ISSN: 1479-6678
PURE UUID: 8a8c5c17-6f88-401d-b7f0-7f1d6aa9a58d
Catalogue record
Date deposited: 09 Aug 2024 16:45
Last modified: 19 Dec 2024 02:40
Export record
Altmetrics
Contributors
Author:
Ahmed Elserwey
Author:
Richard J. Jabbour
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
